Company Requested to Submit White Papers Following IND

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 15, 2012) BioAegis Therapeutics Inc. announced that it has presented its plasma gelsolin technology platform to scientists at the Biological Advanced Research Development Agency (BARDA). Data shared at the meeting demonstrated the ability of plasma to address biological threats, including radiation exposure and potential pandemics. TechWatch meetings enable industry participants to brief the agency on new and innovative technology. The meetings are applied for and granted if the technology is of high interest.